Related content

Neoadjuvant Chemotherapy in Uterine Papillary Serous Carcinoma

By Resnik E.   Taxy J.B.  

Gynecologic Oncology, Vol. 62, Iss. 1, 1996-07 ,pp. : 123-127

Academic Press

Access to resources Recommend Favorite

Complete Clinical Responses to Neoadjuvant Chemotherapy for Uterine Serous Carcinoma

By Price F.V.   Amin R.M.   Sumkin J.  

Gynecologic Oncology, Vol. 73, Iss. 1, 1999-04 ,pp. : 140-144

Elsevier

Access to resources Recommend Favorite

TP53 oncomorphic mutations predict resistance to platinum and taxanebased standard chemotherapy in patients diagnosed with advanced serous ovarian carcinoma

By  

International Journal of Oncology, Vol. 46, Iss. 2, 2015-01 ,pp. : 607-618

Spandidos Publications

Access to resources Recommend Favorite

Neoadjuvant Chemotherapy or Primary Debulking Surgery in Advanced Ovarian Carcinoma: A Retrospective Analysis of 285 Patients

By Vergote I.   De Wever I.   Tjalma W.   Van Gramberen M.   Decloedt J.   van Dam P.  

Gynecologic Oncology, Vol. 71, Iss. 3, 1998-12 ,pp. : 431-436

Elsevier

Access to resources Recommend Favorite

Profile of differentially expressed miRNAs in high-grade serous carcinoma and clear cell ovarian carcinoma, and the expression of miR-510 in ovarian carcinoma

By              

Molecular Medicine Reports, Vol. 12, Iss. 6, 2015-01 ,pp. : 8021-8031

Spandidos Publications

Access to resources Recommend Favorite